Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072975 | 0.85 | KIT (0.44) | CA12CA1CA2CA9KIT | |
| SCHEMBL26072124 | 0.84 | CDK5 (0.46) | KITCDK5CDK5R1PTGS2PTGS1 | |
| SCHEMBL26072969 | 0.77 | FYN (0.53) | CA12CA1CA2CA9KIT | |
| SCHEMBL26072873 | 0.74 | PIK3CA (0.47) | FYN | |
| SCHEMBL8573911 | 0.74 | PTGS2 (0.50) | KITPTGS2PTGS1 | |
| SCHEMBL26072702 | 0.72 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL8308055 | 0.70 | MEN1 (0.60) | CA12CA1CA2CA9CDK5 | |
| SCHEMBL26071976 | 0.69 | ALOX5 (0.36) | CA12CA1CA2CA9KIT | |
| SCHEMBL3997004 | 0.69 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL8306238 | 0.68 | CDK5 (0.60) | CA12CA1CA2CA9CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040267-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CA12 3330/4885CA1 3989/4885CA2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.